GlassScriptPhysician profile
Gianetta Norwood
NPI 1619250289
$7,486.15
in general payments reported to CMS, 2019-2025
65 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,218 · 2024: $3,108 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,195 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,195.24 |
| Education | $290.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $647.81 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $623.50 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $574.46 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $542.36 | 2023-2025 | Lynparza, Calquence, Enhertu |
| Janssen Biotech, INC. | $370.05 | 2023-2025 | Darzalex, Talvey, Erleada |
| Regeneron Healthcare Solutions, INC. | $312.68 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $299.02 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $288.85 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Eisai INC. | $249.18 | 2023-2025 | |
| Abbvie INC. | $241.01 | 2023-2025 | |
| Pfizer INC. | $219.66 | 2023-2025 | |
| Gilead Sciences, INC. | $197.23 | 2024-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $146.13 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $140.41 | 2023 | Imbruvica, Epkinly |
| Tersera Therapeutics LLC | $131.11 | 2023-2024 | Xermelo, Zoladex |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $126.81 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $108.71 | 2023-2025 | Onivyde, Tazverik |
| Beigene USA, INC. | $102.56 | 2023-2025 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $102.29 | 2023-2025 | Padcev, Xtandi |
| Amgen INC. | $100.94 | 2023 | Kyprolis, Lumakras |
| Emd Serono, INC. | $94.75 | 2023-2025 | Bavencio |
| Karyopharm Therapeutics INC. | $90.10 | 2024-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $85.96 | 2024 | Cosela |
| Incyte Corporation | $82.04 | 2023-2025 | Jakafi |
| Exelixis INC. | $79.46 | 2024-2025 | Cabometyx |
| Seagen INC. | $78.63 | 2023 | Padcev, Tukysa |
| Celgene Corporation | $77.25 | 2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $76.88 | 2024-2025 | |
| Genmab U.S., INC. | $75.05 | 2024 | Epkinly |
| Genentech USA, INC. | $67.80 | 2023-2025 | Itovebi, Phesgo, Kadcyla |
| Aveo Pharmaceuticals, INC. | $65.49 | 2024-2025 | |
| Springworks Therapeutics, INC. | $57.24 | 2024-2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $57.22 | 2025 | Besremi |
| Agios Pharmaceuticals, INC. | $56.16 | 2024-2025 | Pyrukynd |
| Amneal Pharmaceuticals LLC | $55.83 | 2025 | Alymsys |
| Glaxosmithkline, LLC. | $55.80 | 2023-2024 | Zejula, Jemperli, Shingrix |
| Blueprint Medicines Corporation | $55.18 | 2023-2025 | Ayvakit |
| Puma Biotechnology, INC. | $48.36 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $47.46 | 2023 | Qinlock |
| Sumitomo Pharma America, INC. | $44.72 | 2023-2024 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $37.72 | 2024 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $33.66 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Immunogen, INC. | $31.07 | 2023 | Elahere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.54 | 2024 | |
| Taiho Oncology, INC. | $29.42 | 2024-2025 | |
| Array Biopharma INC | $28.10 | 2025 | Mektovi, Braftovi, Lorbrena |
| Biocon Biologics INC | $27.68 | 2025 | Fulphila |
| Immunocore Limited | $27.24 | 2025 | Kimmtrak |
| Beone Medicines USA, INC. | $25.54 | 2025 | Brukinsa |
| Tempus Ai, INC | $25.34 | 2024 | |
| Recordati_rare_diseases_inc. | $24.89 | 2023 | Sylvant |
| Stemline Therapeutics INC. | $24.85 | 2025 | Orserdu |
| Novo Nordisk INC | $24.65 | 2023 | |
| Legend Biotech USA INC. | $23.22 | 2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $22.69 | 2025 | Amtagvi |
| G1 Therapeutics, INC. | $21.97 | 2023 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $21.80 | 2024 | |
| Mirati Therapeutics, INC. | $20.97 | 2024 | Krazati |
| Ge Healthcare | $20.62 | 2024 | |
| Adc Therapeutics America, INC. | $20.27 | 2025 | |
| Caris Mpi, INC. | $19.93 | 2025 | Mi Cancer Seek |
| Accord Healthcare, INC. | $19.21 | 2025 | |
| Sobi, INC | $17.80 | 2024 | |
| Myriad Genetic Laboratories, INC. | $16.07 | 2024 | Myrisk |
| Coherus Oncology, INC. | $15.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gianetta Norwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.